The Cholesterol Pill That Could Retire the Needle: What Merck's Enlicitide Data Means for Heart Disease Treatment

There is a number that has defined the limits of cholesterol management for a generation. It is not a clinical threshold or a trial enrollment figure. It is a needle. Every approved PCSK9 inhibitor on the market today requires an injection, typically administered every two to four weeks. The drugs work extraordinarily well. They can cut LDL cholesterol by 50 to 60 percent on top of statin therapy, and they have demonstrated reductions in heart attacks and strokes in large outcomes trials. But the needle has always been the ceiling. Patients who might benefit from PCSK9 inhibition often never receive it, not because the biology is wrong, but because the delivery mechanism creates a barrier that a meaningful proportion of patients and physicians never clear.

On March 30, 2026, Merck presented data at the American College of Cardiology's Annual Scientific Session that may mark the beginning of the end for that ceiling. The CORALreef AddOn trial, the third positive Phase 3 study of enlicitide decanoate, Merck's investigational once-daily oral PCSK9 inhibitor, showed that the drug reduced LDL cholesterol by 64.6 percent from baseline at eight weeks in statin-treated adults with atherosclerotic cardiovascular disease or at high risk for it. The results were published simultaneously in the Journal of the American College of Cardiology. They are not incremental. They are the kind of numbers that reframe what oral cardiovascular medicine can do.

What the CORALreef AddOn Data Actually Show

The trial enrolled 301 adults with hypercholesterolemia who were already on background statin therapy. Investigators randomized patients to receive enlicitide or one of three active comparators: bempedoic acid, ezetimibe, or the combination of both. These are the guideline-recommended oral non-statin options that cardiologists currently reach for when statins alone are insufficient. The comparison was not against placebo. It was against the best available oral alternatives.

Enlicitide won by a wide margin. The 64.6 percent LDL reduction with enlicitide compared to a 36.5 percent reduction with the bempedoic acid and ezetimibe combination, the strongest comparator in the trial. On apolipoprotein B, a secondary endpoint with strong cardiovascular relevance, enlicitide reduced levels by 54.6 percent versus 27.7 percent for the best comparator. Non-HDL cholesterol fell by 58.0 percent with enlicitide versus 31.8 percent for the combination arm. Perhaps most striking, 78.2 percent of patients on enlicitide achieved both a 50 percent or greater reduction in LDL and an absolute LDL below 55 mg/dL, the aggressive target recommended for very high-risk patients. Only 20 percent of patients on the bempedoic acid and ezetimibe combination reached that threshold.

The safety profile was, in the language of the press release, placebo-like. There were no serious adverse events, no discontinuations due to drug-related adverse events, and no new safety signals. Adherence was 98 percent. Enlicitide also reduced lipoprotein(a) by 26.2 percent, a finding of particular interest given that Lp(a) is an independent cardiovascular risk factor for which no approved therapy currently exists.

Why This Is Different From the Existing Oral Options

To understand the significance of these numbers, it helps to understand what enlicitide is and why it has been so difficult to develop. PCSK9 inhibitors work by blocking a protein that degrades LDL receptors on liver cells. More LDL receptors mean more LDL cleared from the blood. The approved injectable PCSK9 inhibitors, evolocumab and alirocumab, are monoclonal antibodies that bind PCSK9 with high affinity. Delivering that kind of binding potency in an oral pill has been a formidable chemistry challenge, because large proteins are degraded in the gastrointestinal tract before they can reach systemic circulation.

Enlicitide is a macrocyclic peptide, a molecular format that sits between a small molecule and a biologic in terms of size and complexity. Merck's chemists designed it to bind PCSK9 with sufficient affinity to achieve injectable-like LDL reductions while remaining stable enough to survive oral administration. The CORALreef Lipids trial, published in the New England Journal of Medicine in February 2026, showed a 57.1 percent LDL reduction versus a 3 percent increase in the placebo group at 24 weeks, with the effect sustained at one year. The CORALreef HeFH trial demonstrated similar efficacy in patients with heterozygous familial hypercholesterolemia, a genetic condition that dramatically elevates cardiovascular risk. Three positive Phase 3 trials across different patient populations, with consistent efficacy and a clean safety record, is a compelling regulatory package.

The Path to Market and What It Would Mean

Merck's chief financial officer said at a TD Cowen conference in early March that the company intended to file for FDA approval of enlicitide imminently. The FDA selected enlicitide to receive a Commissioner's National Priority Voucher in December 2025, a mechanism that can accelerate the review timeline and potentially bring the drug to market ahead of the standard schedule. If the filing proceeds as indicated and the voucher delivers its intended benefit, enlicitide could reach patients in 2026 or early 2027.

The commercial opportunity is substantial. Approximately 86 million adults in the United States have hypercholesterolemia, and nearly 70 percent of patients with established cardiovascular disease who are on lipid-lowering therapy do not reach their LDL targets. The injectable PCSK9 inhibitors have underperformed their commercial potential for years, partly because of cost and partly because of the injection barrier. An oral drug with comparable efficacy and a clean safety profile, priced accessibly, could reach a patient population that the injectables never touched.

Merck is also running CORALreef Outcomes, a large cardiovascular outcomes trial with more than 14,500 participants enrolled, designed to demonstrate that enlicitide's LDL reductions translate into fewer heart attacks and strokes. That data will not be available for years, but the regulatory filing does not require it. The LDL reduction itself is an accepted surrogate endpoint for cardiovascular benefit, and the three completed Phase 3 trials provide the efficacy and safety foundation the FDA needs.

The Broader Implication for Cardiovascular Medicine

The history of cardiovascular pharmacology is, in large part, a history of making effective treatments more accessible. Statins transformed lipid management not just because they worked, but because they were oral, once-daily, and eventually inexpensive. The injectable PCSK9 inhibitors demonstrated that the biology of PCSK9 inhibition was clinically meaningful, but they never achieved the population-level impact that their efficacy data suggested they should. Enlicitide, if it reaches the market with the profile the CORALreef program has established, has the potential to close that gap.

The needle has been the ceiling for PCSK9 inhibition since the first antibody was approved in 2015. The CORALreef AddOn data suggest that ceiling is about to be raised. For the tens of millions of patients whose LDL remains above target despite statin therapy, that is not a minor development. It is the kind of shift that happens once in a generation of cardiovascular medicine.